Search Results for: Global Type 2 Diabetes Market
Articles
Kamada Receives Additional Milestone Payment Under Exclusive Supply & Distribution Agreement June 20, 2017
Kamada Ltd. recently announced the receipt of an undisclosed additional milestone payment under the supply and distribution agreement with Shire...GALECTIN-DIRECTED THERAPIES - Targeting Galectin-3 Protein in Drug Development May 1, 2017
Peter G. Traber, MD, believes we are only at the beginning of understanding the full potential of gal-3 targeted therapy, and the future likely holds additional high affinity, specific, galectin inhibitors that are bioavailable by routes other than the two currently in development.
Neovacs & BioSense Sign Lucrative Option Agreement February 28, 2017
Neovacs recently announced it has signed with BioSense Global LLC a commercial license option agreement for its IFNα Kinoid vaccine...Tiziana Life Sciences Announces New Data With Foralumab, a Fully Human Anti-CD3 Antibody November 21, 2016
Tiziana Life Sciences plc, the clinical-stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, recently announced new data...Mylan & BioCon Announce Regulatory Submission November 11, 2016
Mylan N.V. and Biocon Ltd. recently announced that the European Medicines Agency (EMA) has accepted for review Mylan's Marketing Authorization...Kamada Announces Plan for Phase II/III Clinical Trial November 8, 2016
Kamada Ltd. recently announced the clinical plan for the initiation of a Phase II/III clinical trial in the United States...EXECUTIVE INTERVIEW - Insulet Corporation: Improving Adherence Through Wearable, Patient-Centric Drug Delivery November 7, 2016
Michael Graffeo, Vice President of Business Development, Insulet Delivery Systems Group, discusses the importance of optimizing patient adherence to ensure improved clinical outcomes.
SPECIAL FEATURE - Platform Technologies: Not Just for Big Pharma October 3, 2016
Contributor Cindy H. Dubin recently spoke with several companies that are debunking the theory that access to the latest technological platforms to aid efficient drug discovery and development is limited to Big Pharma, which can more easily justify the costs of creating and operating innovative platforms.
Caladrius Subsidiary, PCT, Announces 5-Year Strategic Manufacturing Services Agreement September 25, 2016
Caladrius Biosciences, Inc., a cell therapy company combining an industry-leading development and manufacturing services provider (PCT, LLC, A Caladrius Company)...SPECIAL FEATURE - Injectable Drug Delivery: Key Trends Define Device Design Now & in the Future August 31, 2016
Contributor Cindy H. Dubin spoke with some of the world’s leading device developers about their current injection technologies and how their devices are addressing the current trends and opportunities in the industry.
Hebei Changshan Biochem Pharma & Albumedix Enter Development Agreement May 20, 2016
Albumedix and Hebei Changshan Biochem Pharma Co. recently announced they have entered into a supply agreement for the development of...EXECUTIVE INTERVIEW - Transdermal Specialties: A New Dimension in Transdermal Drug Delivery May 2, 2016
Bruce K. Redding, Jr, CEO and Founder of TSI, discusses the importance of developing a new tool for enhanced drug delivery, but also a means to reduce the time-to-market for new formulations while also expanding the number of drugs that can be delivered transdermally.
SPECIAL FEATURE - Prefilled Syringes & Parenteral Contract Manufacturing: Biologics Present a New Set of Challenges May 2, 2016
Contributor Cindy H. Dubin speaks with leading syringe developers and contract manufacturers to discuss how they are overcoming industry challenges and provides a look at some of the innovative advancements in prefilled syringe technology.
Chiasma Initiates Second Phase III Trial of Octreotide Capsules March 18, 2016
Chiasma, Inc. recently announced the initiation of a second Phase III clinical trial to investigate the non-inferiority of octreotide capsules...Crown Bioscience Acquires PreClinOmics, Expands Cardiovascular & Metabolic Disease Portfolio March 15, 2016
Crown Bioscience, Inc., a wholly owned subsidiary of Crown Bioscience International, a global drug discovery and development solutions company providing...SPECIAL FEATURE - Advancements in Drug Delivery Technologies Tackle Solubility & Bioavailability Challenges February 29, 2016
Contributor Cindy H. Dubin speaks with several innovator companies to learn more about the latest advances in drug delivery to address the challenging issues of solubility and bioavailability today
Sucampo Enters Exclusive Option & Collaboration Agreement With Cancer Prevention Pharmaceuticals January 18, 2016
Sucampo Pharmaceuticals, Inc. recently announced an option and collaboration agreement under which Cancer Prevention Pharmaceuticals, Inc. (CPP) has granted Sucampo...Egalet Submits NDA for Morphine Sulfate ER Tablets December 16, 2015
Egalet Corporation recently announced the company has submitted an NDA for ARYMO ER (morphine sulfate) extended-release tablets for the management...Caladrius Biosciences Announces Two-Year Study Results December 8, 2015
Caladrius Biosciences, Inc. recently announced the publication of 2-year results from a Phase I clinical study of an autologous Regulatory...Zealand Meets Development Milestone in Collaboration With Boehringer Ingelheim October 16, 2015
Zealand recently announced that Boehringer Ingelheim has selected a novel peptide therapeutic to be advanced into preclinical development under one...Issues
June 2011
When Deals Work - & When They Don't: Large Pharma Strategies for Off-Loading Shuttered Capacity Derek G. Hennecke continues with...
